Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Immunotherapy
- Urinary Bladder Neoplasms
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04706598
- Collaborators
- Shanghai Shen Kang Hospital Development Center
- Investigators
- Study Director: Xiang Wang, MD Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Study Director: Zhong Wang, MD Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine Study Director: Xudong Yao, MD Shanghai Tenth People's Hospital,Shanghai Tong Ji University School of Medicine
Get Well Soon